Oaktree Acquisition III Life Sciences Corp (OACC) FinancialsOACCOaktree Acquisition III Life Sciences Corp

Evaluating the bottom line, Oaktree Acquisition III Life Sciences Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 3.47%, provide a clear picture of how effectively OACC converts its operational activities into shareholder value.

In the context of the broader market, OACC competes directly with industry leaders such as DMAA and FACT. With a market capitalization of $263.50M, it holds a significant position in the sector. When comparing efficiency, OACC's gross margin of N/A stands against DMAA's N/A and FACT's N/A. Such benchmarking helps identify whether Oaktree Acquisition III Life Sciences Corp is trading at a premium or discount relative to its financial performance.

The net income for Q2 2026 is projected at $1,604,621, with an EPS of 0.07. The current ratio has decreased to 0.73, indicating potential liquidity concerns. The debt to equity ratio remains extremely low at 0.01%, showing minimal leverage.